全文获取类型
收费全文 | 85759篇 |
免费 | 9043篇 |
国内免费 | 3034篇 |
专业分类
耳鼻咽喉 | 451篇 |
儿科学 | 1948篇 |
妇产科学 | 618篇 |
基础医学 | 7005篇 |
口腔科学 | 1613篇 |
临床医学 | 8978篇 |
内科学 | 13630篇 |
皮肤病学 | 1260篇 |
神经病学 | 1808篇 |
特种医学 | 3779篇 |
外国民族医学 | 96篇 |
外科学 | 6406篇 |
综合类 | 16316篇 |
现状与发展 | 20篇 |
一般理论 | 4篇 |
预防医学 | 7135篇 |
眼科学 | 940篇 |
药学 | 6958篇 |
58篇 | |
中国医学 | 4159篇 |
肿瘤学 | 14654篇 |
出版年
2024年 | 214篇 |
2023年 | 1634篇 |
2022年 | 2524篇 |
2021年 | 4491篇 |
2020年 | 4097篇 |
2019年 | 3212篇 |
2018年 | 3032篇 |
2017年 | 3384篇 |
2016年 | 3822篇 |
2015年 | 3733篇 |
2014年 | 6015篇 |
2013年 | 6117篇 |
2012年 | 5465篇 |
2011年 | 5838篇 |
2010年 | 4649篇 |
2009年 | 4344篇 |
2008年 | 4204篇 |
2007年 | 4464篇 |
2006年 | 3866篇 |
2005年 | 3507篇 |
2004年 | 2770篇 |
2003年 | 2344篇 |
2002年 | 1915篇 |
2001年 | 1795篇 |
2000年 | 1432篇 |
1999年 | 1077篇 |
1998年 | 997篇 |
1997年 | 915篇 |
1996年 | 717篇 |
1995年 | 679篇 |
1994年 | 623篇 |
1993年 | 446篇 |
1992年 | 501篇 |
1991年 | 426篇 |
1990年 | 361篇 |
1989年 | 327篇 |
1988年 | 316篇 |
1987年 | 281篇 |
1986年 | 236篇 |
1985年 | 192篇 |
1984年 | 157篇 |
1983年 | 109篇 |
1982年 | 111篇 |
1981年 | 84篇 |
1980年 | 89篇 |
1979年 | 81篇 |
1978年 | 50篇 |
1977年 | 50篇 |
1976年 | 38篇 |
1975年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
72.
73.
《Clinical lung cancer》2020,21(6):534-544
BackgroundReliable prediction of progression patterns and failure sites for patients with stage IV lung adenocarcinoma is valuable for physicians to deliver personalized tyrosine kinase inhibitor (TKI) treatment.Patients and MethodsWe retrospectively enrolled 266 patients who had stage IV lung adenocarcinoma and received first-line TKI treatment from 2013 to 2017 in Shanghai Chest Hospital. The clinical characteristics at initial diagnosis, progression patterns, and failure sites were analyzed with the attempt to identify some predictive factors for progression patterns and failure sites.ResultsAmong all patients, 62.4% developed systemic progression, and 37.6% developed oligoprogression. Both cohorts had a median progression-free survival (PFS) of 9 months. The percentage of patients who developed original and distant failure was 39.1% and 60.9%, respectively. Patients with oligometastasis at initial diagnosis were more prone to develop oligoprogression (odds ratio [OR], 4.370; 95% confidence interval [CI], 1.881-10.151; P = .001), whereas pulmonary metastasis was negatively correlated with oligoprogression (OR, 0.567; 95% CI, 0.330-0.974; P = .04). Both oligometastasis diagnosis (OR, 2.959; 95% CI, 1.347-6.500; P = .007) and the maximum diameter of the primary lung lesion (threshold 3.25 cm: OR, 3.646; 95% CI, 2.041-6.515; P = .0001) were strong predictive factors for original failures. Osseous metastasis at initial diagnosis might be an indication for distant failure (OR, 0.536; 95% CI, 0.316-0.909; P = .021).ConclusionOver one-half of patients with stage IV lung adenocarcinoma receiving first-line TKI treatment developed systemic progression and distant failure. Metastasis patterns at initial diagnosis was the most important predictive factor for progression patterns and failure sites. The maximum diameter of the primary lung lesion and evidence of osseous metastasis were also found to be significant indicative factors for failure sites. 相似文献
74.
Nirmanmoh Bhatia Buddhadeb Dawn Tariq S. Siddiqui Marcus F. Stoddard 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(1):16-24
Determining aortic stenosis (AS) severity is clinically important. Calculating aortic valve (AV) area by means of the continuity equation assumes a circular left ventricular outflow tract (LVOT). The full impact of this assumption in calculating AV area is unknown. Predictors of noncircular LVOT shape in patients with AS are undefined.In 109 adult patients with AS who underwent multiplanar transesophageal echocardiography, we calculated AV area by means of the standard continuity method and by a modified method involving planimetric LVOT area.We found 54 circular, 37 horizontal-oval, 8 vertical-oval, and 10 irregular LVOTs. Area derived by direct planimetry correlated better with the modified than the standard continuity method (r=0.89 vs r=0.85; both P=0.0001). Valve areas of patients with mild, moderate, or severe AS by planimetry were more often mischaracterized with use of the standard than modified method (29 vs 18; P <0.0001). Horizontal-oval AV area derived by planimetry (1.28 ± 0.55 cm2) was underestimated by the standard method (1.05 ± 0.47 cm2; P=0.001), but not by the modified method. Congenital AV morphology and low cardiac index were the only multivariate predictors of horizontal-oval shape. Low cardiac index was the only predictor of noncircular shape.More than half our patients with AS had noncircular LVOTs. Using the modified method reduces mischaracterizations of AS severity. Congenital AV morphology and low cardiac index predict horizontal-oval or noncircular shape. These data suggest the value of direct LVOT measurement to calculate AS severity in patients who have congenital AV or a low cardiac index. 相似文献
75.
Treatment of posterior eye diseases is more challenging than the anterior segment ailments due to a series of anatomical barriers and physiological constraints confronted by drug delivery to the back of the eye. In recent years, concerted efforts in drug delivery have been made to prolong the residence time of drugs injected in the vitreous humor of the eye. Our previous studies demonstrated that poly(ortho ester) (POE) nanoparticles were biodegradable/biocompatible and were capable of long-term sustained release. The objective of the present study was to investigate the safety and localization of POE nanoparticles in New Zealand white rabbits and C57BL/6 mice after intravitreal administration for the treatment of chronic posterior ocular diseases. Two concentration levels of POE nanoparticles solution were chosen for intravitreal injection: 1.5?mg/ml and 10?mg/ml. Our results demonstrate that POE nanoparticles were distributed throughout the vitreous cavity by optical coherence tomography (OCT) examination 14 days post-intravitreal injection. Intraocular pressure was not changed from baseline. Inflammatory or adverse effects were undetectable by slit lamp biomicroscopy. Furthermore, we demonstrate that POE nanoparticles have negligible toxicity assessed at the cellular level evidenced by a lack of glia activation or apoptosis estimation after intravitreal injection. Collectively, POE nanoparticles are a novel and nontoxic as an ocular drug delivery system for the treatment of posterior ocular diseases. 相似文献
76.
Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth
factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib
monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily
pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective
analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib
(250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second or
more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response
rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival
(mOS), and safety were analyzed. A total of 26 eligible patients were included: 24 patients diagnosed with
adenocarcinoma, 2 with squamous carcinoma, and 14 patients harboring EGFR sensitizing mutations. The
mPFS and mOS were 4.93 (range, 0.27−32.91; 95% CI 3.64−6.22) and 14.70 (range, 0.27−32.91; 95% CI
0.27−43.60) months for the whole group. The ORR and DCR were 7.7% (2/26) and 69.2% (18/26) for the
entire lesions, and 7.7% (2/26) and 79.6% (20/26) for brain metastases, respectively. Compared with patients
who received apatinib monotherapy, patients who received apatinib combination treatment had more favorable
mPFS (11.77 vs. 2.27 months, p<0.05) and mOS (24.03 vs. 6.07 months, p<0.05). Treatment-related toxicities
were tolerable including grade 1/2 hypertension, hand-and-foot syndrome, fatigue, nausea, liver dysfunction,
myelosuppression, skin rash, and palpitation. In conclusion, apatinib exhibited high activity and good tolerance
for NSCLC patients with brain metastasis, and it might become a potential choice for metastatic brain tumors
in NSCLC patients. 相似文献
77.
78.
79.
80.
目的:观察疏风宣肺止嗽汤对咳嗽变异性哮喘患儿肺功能及睡眠质量的影响。方法:将70例咳嗽变异性哮喘患儿按照随机数字表法分为对照组和观察组,每组各35例。对照组给予常规西医治疗,观察组在对照组的基础上加用自拟疏风宣肺止嗽汤治疗。比较两组患儿的临床疗效、症状消失时间、住院时间、不良反应发生率、复发率及治疗前后中医证候积分、匹兹堡睡眠质量指数(pittsburgh sleep quality index,PSQI)、肺功能指标变化情况。结果:观察组有效率为94.29%,对照组有效率为77.14%,两组患儿有效率比较,差异具有统计学意义(P<0.05)。观察组复发率低于对照组,差异具有统计学意义(P<0.05)。两组患儿治疗后中医证候评分及PSQI评分低于本组治疗前,且观察组治疗后低于对照组治疗后,差异具有统计学意义(P<0.05)。两组患儿治疗后肺功能指标高于本组治疗前,且观察组治疗后高于对照组治疗后,差异具有统计学意义(P<0.05)。观察组患儿症状消失时间及住院时间短于对照组,差异具有统计学意义(P<0.05)。结论:自拟疏风宣肺止嗽汤治疗咳嗽变异性哮喘,能够改善患儿的临床症状、肺功能及睡眠质量。 相似文献